|
Orthologous residues
|
|
MCL1 (human): S159‑p, MCL1 iso2 (human): S159‑p, MCL1 (mouse): S140‑p, MCL1 (rat): S139‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
FL5.12 (lymphoid), HeLa (cervical), Jurkat (T lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
GSK3B (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
LY294002, MG132
|
|
|
|
increase
|
|
|
LY294002, CHIR-611
|
|
|
|
decrease
|
|
|
LY294002, MG132, CHIR-611
|
|
|
|
decrease
|
|
|
IL-3 withdrawal
|
|
|
|
increase
|
|
|
LY294002, IL-3 withdrawal, CHIR-611
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
protein degradation
|
|
Effect of modification (process):
apoptosis, altered
|
